Published in Drug Week, November 25th, 2005
EVIZON with concomitant PDT was well-tolerated in all subjects with no drug-related serious adverse events reported to date. The most common adverse events involved infusion site reactions. These events were generally mild and were distributed evenly across the EVIZON plus PDT treatment groups. Preliminary data were presented for 40 mg or 20 mg of EVIZON with concomitant PDT compared with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.